Clinical TrialsThe most recent clinical data for the vepdegestrant and palbociclib combination showed a consistent CBR rate and tolerability profile showing its potential in early line settings.
Product PotentialARV-102's mechanism of action may avoid lung pneumocyte effects seen with kinase inhibitors, allowing for lower dosing due to the degrader's catalytic activity.
Research And DevelopmentThe 'full dose' of both agents demonstrated a manageable safety profile, suggesting there were no drug-drug interactions observed.